Aquestive Therapeutics Overview
- Status
-
Public
- Employees
-
147
- Stock Symbol
-
AQST
- Investments
-
4
- Share Price
-
$3.47
- (As of Friday Closing)
Aquestive Therapeutics General Information
Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Contact Information
Website
www.aquestive.comCorporate Office
- 30 Technology Drive
- Warren, NJ 07059
- United States
Corporate Office
- 30 Technology Drive
- Warren, NJ 07059
- United States
Aquestive Therapeutics Stock Performance
As of 20-Nov-2026, Aquestive Therapeutics’s stock price is $3.47. Its current market cap is $435M with 126M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.47 | $3.71 | $2.93 - $6.74 | $435M | 126M | 2.41M | -$0.64 |
Aquestive Therapeutics Financials Summary
As of 30-Sep-2026, Aquestive Therapeutics has a trailing 12-month revenue of $48.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 541,660 | 700,453 | 283,570 | 154,990 |
| Revenue | 48,837 | 44,545 | 57,561 | 50,583 |
| EBITDA | (66,883) | (70,503) | (30,053) | (15,139) |
| Net Income | (79,277) | (83,784) | (44,137) | (7,870) |
| Total Assets | 119,327 | 160,425 | 101,424 | 57,418 |
| Total Debt | 58,772 | 42,481 | 38,004 | 33,319 |
Aquestive Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aquestive Therapeutics Comparisons
Industry
Financing
Details
Aquestive Therapeutics Competitors (45)
One of Aquestive Therapeutics’s 45 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Sanofi | Corporation | Gentilly, France | ||||
| Vanda Pharmaceuticals | Formerly VC-backed | Washington, DC | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Cipla | Corporation | Mumbai, India |
Aquestive Therapeutics Patents
Aquestive Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260108458-A1 | Methods of administering enhanced delivery epinephrine and prodrug compositions to treat allergy | Pending | 23-Oct-2024 | ||
| WO-2026090387-A1 | Methods of administering enhanced delivery epinephrine and prodrug compositions to treat allergy | Pending | 23-Oct-2024 | ||
| US-20260108422-A1 | Pharmaceutical film storage and dispenser device | Pending | 21-Oct-2024 | ||
| WO-2026090119-A1 | Pharmaceutical film storage and dispenser device | Pending | 21-Oct-2024 | ||
| US-20260027045-A1 | Methods of administering enhanced delivery epinephrine and prodrug compositions | Pending | 23-Jul-2024 | A61K9/006 |
Aquestive Therapeutics Signals
Aquestive Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aquestive Therapeutics Investments (4)
Aquestive Therapeutics’s most recent deal was a Corporate Asset Purchase with Aquestive Therapeutics (U.S. Patent for Multifunctional Single Layer Film Drug Delivery Technology). The deal was made on 20-Dec-2012.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aquestive Therapeutics (U.S. Patent for Multifunctional Single Layer Film Drug Delivery Technology) | 20-Dec-2012 | Corporate Asset Purchase | Buildings and Property | ||
| Adept Polymers | 29-May-2007 | Buyout/LBO | Other Materials | ||
| Stanelco (Certain Equipment and Intellectual Property) | 29-May-2007 | Buyout/LBO | Other Containers and Packaging | ||
| RespondTV | 26-Jul-2000 | Later Stage VC | Social Content |
Aquestive Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Aquestive Therapeutics Exits (1)
Aquestive Therapeutics’s most recent exit was on 26-Jul-2000 from RespondTV. The exit was categorized as with 8 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| RespondTV | 26-Jul-2000 | Completed |
|
Aquestive Therapeutics FAQs
-
Where is Aquestive Therapeutics headquartered?
Aquestive Therapeutics is headquartered in Warren, NJ.
-
What is the size of Aquestive Therapeutics?
Aquestive Therapeutics has 147 total employees.
-
What industry is Aquestive Therapeutics in?
Aquestive Therapeutics’s primary industry is Drug Delivery.
-
Is Aquestive Therapeutics a private or public company?
Aquestive Therapeutics is a Public company.
-
What is Aquestive Therapeutics’s stock symbol?
The ticker symbol for Aquestive Therapeutics is AQST.
-
What is the current stock price of Aquestive Therapeutics?
As of 20-Nov-2026 the stock price of Aquestive Therapeutics is $3.47.
-
What is the current market cap of Aquestive Therapeutics?
The current market capitalization of Aquestive Therapeutics is $435M.
-
What is Aquestive Therapeutics’s current revenue?
The trailing twelve month revenue for Aquestive Therapeutics is $48.8M.
-
Who are Aquestive Therapeutics’s competitors?
Crinetics Pharmaceuticals, Sanofi, Vanda Pharmaceuticals, Novartis, and Cipla are some of the 45 competitors of Aquestive Therapeutics.
-
What is Aquestive Therapeutics’s annual earnings per share (EPS)?
Aquestive Therapeutics’s EPS for 12 months was -$0.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process